

# Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

NCT06989840

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Sagimet Biosciences Inc.
Enrollment	128 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Healthy Participants (Parts A, B and C)
  - Healthy, adult, male or female 18-55 years of age
  - Body mass index (BMI)  $\geq 18.0$  and  $\leq 32.0$  kg/m<sup>2</sup>
  - Medically healthy with no clinically significant medical history
  - Understands the study procedures in the informed consent form (ICF) and willing and able to comply with the protocol
- ... and 3 more (see full listing online)

### Exclusion (16)

- Healthy Participants (Parts A, B and C)
  - History or presence of clinically significant medical or psychiatric condition or disease
  - History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds including over the counter acne products.
  - Has a clinically significant ophthalmic examination finding
  - Female participant of childbearing potential
- ... and 11 more (see full listing online)

## Locations (2 total)

---

Celerion, Inc., Tempe, Arizona, United States  
Nucleus Network, Melbourne, Victoria, Australia